Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

被引：24
|
作者：
Sharma, Vinod [1 ]
Vanidassane, Ilavarasi [1 ]
机构：
[1] All India Inst Med Sci, New Delhi, India
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 382卷 / 09期
关键词：
D O I：
10.1056/NEJMc1915676
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
To the Editor: Kopetz et al. (Oct. 24 issue)(1) found an overall survival benefit of triplet therapy (encorafenib, binimetinib, and cetuximab) as compared with control therapy (cetuximab with either irinotecan or FOLFIRI [folinic acid, fluorouracil, and irinotecan]) among patients with BRAF-mutated colorectal cancer. The trial also included a third group that received doublet therapy (encorafenib and cetuximab). Although the trial was not powered to compare the triplet-therapy group with the doublet-therapy group, a number of observations favor the doublet-therapy group. First, among more than 200 patients in each group, the median progression-free survival was similar in the doublet-therapy group and . . .
引用
收藏
页码：876 / 876
页数：1
相关论文
共 50 条
  • [31] Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E-Mutated Metastatic Colorectal Cancer
    Akhoundova, Dilara
    Pietge, Heike
    Hussung, Saskia
    Kiessling, Michael
    Britschgi, Christian
    Zoche, Martin
    Rechsteiner, Markus
    Weber, Achim
    Fritsch, Ralph M.
    JCO PRECISION ONCOLOGY, 2021, 5 : 1082 - 1087
  • [32] BRAF V600E-mutated Colorectal Neuroendocrine Carcinoma Effectively Treated with a Chemotherapy Protocol for BRAF-mutated Metastatic Colorectal Cancer
    Owaki, Seira
    Mori, Yoshinori
    Nakai, Shunsuke
    Maeda, Hideki
    Imazu, Mitsuki
    Tomita, Yusaku
    Kanaiwa, Hiroki
    Yamaguchi, Ayana
    Kitagawa, Mika
    Hirano, Atsuyuki
    Kimura, Yoshihide
    Tsuchida, Kenji
    Kataoka, Hiromi
    INTERNAL MEDICINE, 2024, 63 (14) : 1995 - 1999
  • [33] Influence of sex on safety and efficacy in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with encorafenib-cetuximab plus /-binimetinib (E-C plus /-B)
    Montana, F. J. Ros
    Navarro, V.
    Comas, R.
    Rodriguez, A. Garcia
    Gomez, D.
    Gonzalez, N. Saoudi
    Vicente, P.
    Cuadra, J. L.
    Paez, D.
    Alonso, V.
    Martinez, A. Hernandez
    Valbuena, D. E. Lopez
    Argota, I. Baraibar
    Ballabrera, F. Salva
    Tabernero, J.
    Fernandez, M. E. Elez
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S707 - S707
  • [34] BRAF K601E-mutated metastatic colorectal cancer in response to combination therapy with encorafenib, binimetinib, and cetuximab: A case report
    Sasaki, Makiko
    Shimura, Takaya
    Nishie, Hirotada
    Kuroyanagi, Keita
    Kanno, Takuya
    Fukusada, Shigeki
    Sugimura, Naomi
    Mizuno, Yusuke
    Nukui, Takayuki
    Uno, Konomu
    Kojima, Yuki
    Nishigaki, Ruriko
    Tanaka, Mamoru
    Ozeki, Keiji
    Kubota, Eiji
    Kataoka, Hiromi
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 16 (07)
  • [35] Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer
    Yukimoto, Ryohei
    Nishida, Naohiro
    Hata, Tsuyoshi
    Fujino, Shiki
    Ogino, Takayuki
    Miyoshi, Norikatsu
    Takahashi, Hidekazu
    Uemura, Mamoru
    Satoh, Taroh
    Hirofumi, Yamamoto
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Eguchi, Hidetoshi
    CANCER SCIENCE, 2021, 112 (07) : 2884 - 2894
  • [36] Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report
    Gallois, Claire
    Taieb, Julien
    Sabouret, Annabelle
    Broudin, Chloe
    Karoui, Mehdi
    Garinet, Simon
    Zaanan, Aziz
    GENES CHROMOSOMES & CANCER, 2022, 61 (02): : 114 - 118
  • [37] Treatment with encorafenib and cetuximab of a non-anti-epidermal growth factor receptor-naive patient for BRAF V600E-mutated metastatic colon cancer
    El-khoury, Reem
    Hafliger, Emilie
    Gallois, Claire
    Louafi, Samy
    Garinet, Simon
    Zaanan, Aziz
    Taieb, Julien
    EUROPEAN JOURNAL OF CANCER, 2021, 152 : 1 - 3
  • [38] Co-existence of BRAF V600E-mutated malignant melanoma and BRAF V600E-mutated Langerhans cell histiocytosis: A case report
    Goto, Keisuke
    Yoshikawa, Shusuke
    Kiyohara, Yoshio
    Kukita, Yoji
    Miura, Keiko
    Oishi, Takuma
    JOURNAL OF CUTANEOUS PATHOLOGY, 2022, 49 (04) : 393 - 398
  • [39] Safety and efficacy of encorafenib, binimetinib, plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer: Results of a prospective study as an expanded access program
    Takashima, Atsuo
    Kotani, Daisuke
    Kato, Takeshi
    Satoh, Taroh
    Masuishi, Toshiki
    Komatsu, Yoshito
    Shiozawa, Manabu
    Esaki, Taito
    Izawa, Naoki
    Takeuchi, Shinji
    Bando, Hideaki
    Iwasa, Satoru
    Hasegawa, Hiroko
    Yamaguchi, Toshifumi
    Taniguchi, Hiroya
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [40] Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP follow-up study
    Kato, T.
    Kotani, D.
    Takashima, A.
    Satoh, T.
    Masuishi, T.
    Komatsu, Y.
    Shiozawa, M.
    Esaki, T.
    Izawa, N.
    Takeuchi, S.
    Bando, H.
    Iwasa, S.
    Hasegawa, H.
    Yamaguchi, T.
    Taniguchi, H.
    Yamada, S.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S21 - S22
12345